Serum lncRNA TINCR Serve as a Novel Biomarker for Predicting the Prognosis in Triple-Negative Breast Cancer

Wang, Xiaojie; Li, Shuang; Xiao, Huiyu; Deng, Xiaoqin

doi:10.1177/1533033820965574

Cited by 24 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the lncRNAs involved in the model, several of them were reported to be associated with tumor progression, such as lncRNA TINCR [ 43 – 45 ] and TUG1 [ 46 – 48 ]. A recent study revealed that serum lncRNA TINCR level was significantly increased in TNBC and correlated with clinical outcome [ 49 ]. Tang et al [ 50 ] reported that lncRNA TUG1 could act as a miR-197 sponge to enhance cisplatin sensitivity in TNBC.…”

Section: Discussionmentioning

confidence: 99%

Development of a Prognostic Model Based on the Identification of EMT-Related lncRNAs in Triple-Negative Breast Cancer

Guo

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Background. Triple-negative breast cancer (TNBC) remains the most incurable subtype of breast cancer owing to high heterogeneity, aggressive nature, and lack of treatment options. It is generally acknowledged that epithelial-mesenchymal transition (EMT) is the key step in tumor metastasis. Methods. With the application of TCGA and GEO databases, we identified EMT-related lncRNAs by the Cox univariate regression analysis. Optimum risk scores were calculated and used to divide TNBC patients into high-/low-risk subgroups by the median value using the Lasso regression analysis. The Kaplan–Meier and ROC curve analyses were applied for model validation. Then, we assessed the risk model from multi-omic aspects including immune infiltration, drug sensitivity, mutability spectrum, signaling pathways, and clinical indicators. We also analyzed the expression pattern of lncRNAs involved in the model using qRT-PCR in TNBC cell lines and constructed the ceRNA network. Results. The risk model was composed of EMT-related long noncoding RNAs (lncRNAs), which seemed to be valuable in the prognostic prediction of TNBC patients. The model could act as an independent prognostic factor of TNBC and showed a robust prognostic ability in the stratification analysis. Further investigation demonstrated that the expression of lncRNAs was different between high aggressive and low aggressive TNBC cell lines, as well as TNBC patients. Conclusions. Together, our study successfully established a risk model with great accuracy and efficacy in the prognostic prediction of TNBC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a Prognostic Model Based on the Identification of EMT-Related lncRNAs in Triple-Negative Breast Cancer

Guo

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Recently, the expression analysis performed in the serum samples from 72 TNBC, 105 non-TNBC, 60 benign breast disease patients and 86 healthy subjects evidenced that higher lncRNA TINCR levels are detectable in BC patients, especially in TNBC, compared to subjects without cancer [ 91 ]. High circulating TINCR was significantly correlated with clinicopathological features and with poor OS in TNBC.…”

Section: Circulating Non-coding Rnas As Biomarkers In Tnbcmentioning

confidence: 99%

Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer

Agostino

Vahabi²,

Turco³

et al. 2022

ncRNA

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a subtype of breast carcinoma characterized by poor prognosis and high rate of metastasis. Current treatment is based on chemo- and/or radiotherapy and surgery. TNBC is devoid of estrogen, progesterone and HER2 receptors. Although precision medicine has come a long way to ameliorate breast cancer disease management, targeted therapies for the treatment of TNBC patients are still limited. Mounting evidence has shown that non-coding RNAs (ncRNAs) drive many oncogenic processes at the basis of increased proliferation, invasion and angiogenesis in TNBC, strongly contributing to tumor progression and resistance to treatments. Many of these ncRNAs are secreted in the tumor microenvironment (TME) and impinge on the activity of the diverse immune and stromal cell types infiltrating the TME. Importantly, secreted ncRNAs may be detected as circulating molecules in serum/plasma from cancer patients and are emerging a promising diagnostic/therapeutic tools in TNBC. This review aims to discuss novel insights about the role of secreted circulating ncRNAs in the intercellular communication in the tumor microenvironment and their potential clinical use as diagnostic and prognostic non-invasive biomarkers in TNBC.

show abstract

“…On the other hand, changes in ncRNA expression after the therapy can be a valuable precursor of tumor recurrence. In the Table 2 we summarized the recent studies analyzing the utility of circulating ncRNAs for TNBC prediction and prognosis [57,70,[78][79][80][81][82][83][84].…”

Section: Circulating Ncrnas For Tnbc Prediction and Prognosismentioning

confidence: 99%

“…Data regarding the utility of lncRNAs for prediction and prognosis is still limited and only few papers have focused on this idea [70,[83][84][85]. Among the lncRNAs, the TINCR seems to be the most promising TNBC-related lncRNA, serving as a diagnostic and prognostic biomarker.…”

Section: Lncrnasmentioning

confidence: 99%

Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer

Powrózek

Otieno

2022

Cancers

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer, and is related to unfavorable prognosis and limited treatment strategies. Currently, there is a lack of reliable biomarkers allowing for the clinical management of TNBC. This is probably caused by a complex molecular background, leading to the development and establishment of a unique tumor phenotype. Recent studies have reported non-coding RNAs (ncRNAs) not only as the most promising class of molecular agents with a high applicability to manage human cancers, including TNBC, but also as robust and non-invasive biomarkers that are able to be monitored in blood circulation, with the application of liquid biopsy. There is a lack of papers discussing the role of blood-circulating ncRNAs as diagnostic, predictive, and prognostic biomarkers for TNBC. In this paper, we summarized the available literature reports on the utility of blood-circulating ncRNAs for TNBC management. Additionally, we supplemented this review by bioinformatics analysis, for better understanding of the role of ncRNAs’ machinery in the development of a unique TNBC phenotype.

show abstract

Serum lncRNA TINCR Serve as a Novel Biomarker for Predicting the Prognosis in Triple-Negative Breast Cancer

Cited by 24 publications

References 24 publications

Development of a Prognostic Model Based on the Identification of EMT-Related lncRNAs in Triple-Negative Breast Cancer

Development of a Prognostic Model Based on the Identification of EMT-Related lncRNAs in Triple-Negative Breast Cancer

Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer

Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer

Contact Info

Product

Resources

About